Common Market - Connect Four (Remix) Lyrics: I look up the at sky and I see the wants and needs Everything for me someone come and set me free I live inside a cage where my path is not my choice A fear of doing what I love to do is growing more But I can't be bothered can I? I have to push and strive Ignore what people say cause they're not the ones to decide My life and how it'll turn out to be when we're all grown up I need to ignore them and just straight not give a fuck I mean I don't even care if you don't like what I am spittin' My lyrics are for me not you so why you trippin'? If you don't like it take your shit and move along Cause really, your wasting time with your bitching wearing thongs And I talk about my dreams, and I talk about them girls I can talk about anything that I want you fucking squirrel Well you look like a squirrel no maybe a giraffe Nah you look like a joke when you swag cook to the max So did I set it straight for you do you get my idea? Go dick ride some more with your boyfriend at ikea And say it to my face and not right behind my back You know that shit revolves around to me that's a fact I'm glad that it did now I know the good and fakes I know the wrong and rights and the ones that have no face No meaning in my life, and I could really care less I hope you know that other people hate you to confess But, I realize that you're in a stressful time So you're off the hook for now but still realize That I'm not gonna stop making songs in the ...

Register for this CCAR Seminar here: tinyurl.com The Contra Costa Association of Realtors sponsors workshops and seminars that enable Realtors and business owners to be successful with social media and online marketing. fb.com These classes always include a tremendous amount of information on exactly what you should do, why it works, and how to get started. Each class offers a collection of tips, strategies and tools available to you in the world of social media and internet marketing The first seminar in this series is "How to Engage Your Market, Connect With Customers and Grow Your Business" Bring your notepad, curiosity and questions and learn some of the most effective social media and online marketing strategies, resources and best practices for attracting more business and sales The first seminar in this series of seven classes is FREE...In this introductory seminar we cover these topics... Blogs and websites LinkedIn YouTube and video marketing Mobile media and text message marketing Google Twitter Facebook Zillow Active Rain Craigslist And how to integrate traditional print media marketing The other upcoming seminars include... "How to Build Your LinkedIn Foundation to Grow Your Business" In this seminar you will discover... How to Optimize Your LinkedIn Profile for maximum exposure and top search ranking using targeted keywords The secrets to leveraging LinkedIn Recommendations Tips on integrating LinkedIn into the rest of your Social Media Strategy The "How to ...

Chief Scientific Officer (CSO) for OmniBio Dr. Charles Dinarello discusses Alpha-1 Antitrypsin (AAT) research and it's potential as a therapy for Type 1 diabetes. He is also a Professor of Medicine and Immunology at the University of Colorado Denver who has published over 700 original research articles on cytokines, particularly interleukin‐1 (IL‐1) and tumor necrosis factor, and is considered a "founding father" of cytokine biology. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

Dr. Charles Dinarello, Chief Scientific Officer of OmniBio, is a co-author of an article that is now available in the journal Blood, which is the premier journal of the American Society of Hematology. The paper describes the use of Alpha 1 antitrypsin (AAT) to treat mice with a lethal form of rejection of bone marrow transplantation. Mice survive the crisis with AAT treatment. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com

OmniBio CEO Dr. James Crapo talks about the important research taking place with Alpha-1 Antitrypsin (AAT). This safe and powerful molecule is being used in trials for type 1 diabetes and Graph vs. Host disease (GVH). OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: OmniBioPharma.com Facebook goo.gl LinkedIn: goo.gl Visit OmniBioPharma.com for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: WestMountainAM.com Twitter: WestMountainAM.com LinkedIn: WestMountainAM.com Blog: WestMountainAM.com